The renin-angiotensin-aldosterone system: An old tree sprouts new shoots

IF 4.4 2区生物学 Q2 CELL BIOLOGY

Cellular signalling Pub Date : 2024-09-19 DOI:10.1016/j.cellsig.2024.111426

Yaqing Ruan , Yongxin Yu , Meiqin Wu , Yulang Jiang , Yuliang Qiu , Shiwei Ruan

{"title":"The renin-angiotensin-aldosterone system: An old tree sprouts new shoots","authors":"Yaqing Ruan , Yongxin Yu , Meiqin Wu , Yulang Jiang , Yuliang Qiu , Shiwei Ruan","doi":"10.1016/j.cellsig.2024.111426","DOIUrl":null,"url":null,"abstract":"<div><div>The intricate physiological and pathological diversity of the Renin-Angiotensin-Aldosterone System (RAAS) underpins its role in maintaining bodily equilibrium. This paper delves into the classical axis (Renin-ACE-Ang II-AT1R axis), the protective arm (ACE2-Ang (1–7)-MasR axis), the prorenin-PRR-MAP kinases ERK1/2 axis, and the Ang IV-AT4R-IRAP cascade of RAAS, examining their functions in both physiological and pathological states. The dysregulation or hyperactivation of RAAS is intricately linked to numerous diseases, including cardiovascular disease (CVD), renal damage, metabolic disease, eye disease, Gastrointestinal disease, nervous system and reproductive system diseases. This paper explores the pathological mechanisms of RAAS in detail, highlighting its significant role in disease progression. Currently, in addition to traditional drugs like ACEI, ARB, and MRA, several novel therapeutics have emerged, such as angiotensin receptor-enkephalinase inhibitors, nonsteroidal mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, aminopeptidase A inhibitors, and angiotensinogen inhibitors. These have shown potential efficacy and application prospects in various clinical trials for related diseases. Through an in-depth analysis of RAAS, this paper aims to provide crucial insights into its complex physiological and pathological mechanisms and offer valuable guidance for developing new therapeutic approaches. This comprehensive discussion is expected to advance the RAAS research field and provide innovative ideas and directions for future clinical treatment strategies.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"124 ","pages":"Article 111426"},"PeriodicalIF":4.4000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular signalling","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0898656824003942","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The intricate physiological and pathological diversity of the Renin-Angiotensin-Aldosterone System (RAAS) underpins its role in maintaining bodily equilibrium. This paper delves into the classical axis (Renin-ACE-Ang II-AT1R axis), the protective arm (ACE2-Ang (1–7)-MasR axis), the prorenin-PRR-MAP kinases ERK1/2 axis, and the Ang IV-AT4R-IRAP cascade of RAAS, examining their functions in both physiological and pathological states. The dysregulation or hyperactivation of RAAS is intricately linked to numerous diseases, including cardiovascular disease (CVD), renal damage, metabolic disease, eye disease, Gastrointestinal disease, nervous system and reproductive system diseases. This paper explores the pathological mechanisms of RAAS in detail, highlighting its significant role in disease progression. Currently, in addition to traditional drugs like ACEI, ARB, and MRA, several novel therapeutics have emerged, such as angiotensin receptor-enkephalinase inhibitors, nonsteroidal mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, aminopeptidase A inhibitors, and angiotensinogen inhibitors. These have shown potential efficacy and application prospects in various clinical trials for related diseases. Through an in-depth analysis of RAAS, this paper aims to provide crucial insights into its complex physiological and pathological mechanisms and offer valuable guidance for developing new therapeutic approaches. This comprehensive discussion is expected to advance the RAAS research field and provide innovative ideas and directions for future clinical treatment strategies.

查看原文本刊更多论文

肾素-血管紧张素-醛固酮系统：老树发新芽

肾素-血管紧张素-醛固酮系统（RAAS）具有错综复杂的生理和病理多样性，是其维持身体平衡的基础。本文深入探讨了 RAAS 的经典轴（Renin-ACE-Ang II-AT1R 轴）、保护臂（ACE2-Ang (1-7)-MasR 轴）、促肾素-PRR-MAP 激酶 ERK1/2 轴和 Ang IV-AT4R-IRAP 级联，研究了它们在生理和病理状态下的功能。RAAS 的失调或过度激活与多种疾病密切相关，包括心血管疾病（CVD）、肾损伤、代谢性疾病、眼部疾病、胃肠道疾病、神经系统和生殖系统疾病。本文详细探讨了 RAAS 的病理机制，强调了 RAAS 在疾病进展中的重要作用。目前，除了 ACEI、ARB 和 MRA 等传统药物外，还出现了一些新型治疗药物，如血管紧张素受体-脑啡肽酶抑制剂、非类固醇类矿物皮质激素受体拮抗剂、醛固酮合成酶抑制剂、氨肽酶 A 抑制剂和血管紧张素原抑制剂。这些药物在各种相关疾病的临床试验中显示出了潜在的疗效和应用前景。本文旨在通过对 RAAS 的深入分析，提供对其复杂生理和病理机制的重要见解，并为开发新的治疗方法提供有价值的指导。本文的全面论述有望推动 RAAS 研究领域的发展，并为未来的临床治疗策略提供创新思路和方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular signalling 生物-细胞生物学

CiteScore

8.40

自引率

0.00%

发文量

250

审稿时长

27 days

期刊介绍： Cellular Signalling publishes original research describing fundamental and clinical findings on the mechanisms, actions and structural components of cellular signalling systems in vitro and in vivo. Cellular Signalling aims at full length research papers defining signalling systems ranging from microorganisms to cells, tissues and higher organisms.